ADVFN - Advanced Financial Network.
HOME» NYSE » A » AGN Stock Price » AGN Stock News

Allergan Share News

 Allergan, Stock Price
AGN Stock Price
 Allergan, Stock Chart
AGN Stock Chart
 Allergan, Stock News
AGN Stock News
 Allergan, Company Information
AGN Company Information
 Allergan, Stock Trades
AGN Stock Trades

Inspire Pharma: Dry-Eye Treatment Didn't Meet Study Endpoints

DOW JONES NEWSWIRES Inspire Pharmaceuticals Inc. (ISPH) said its Prolacria treatment for dry eye met neither the primary nor secondary endpoints in a late-stage trial. Shares fell 7.5% to $6.11 premarket. Shares in its partner in developing the eye drops, Allergan Inc. (AGN), weren't active after closing Wednesday at $61.20. Early data about Prolacria had been discouraging, so the final results won't come as a huge surprise, but the treatment had been one of Inspire's most advanced drugs in its pipeline. Its other advanced drug candidate is denufosol tetrasodium for cystic fibrosis. Inspire focuses on developing treatments for ophthalmic and pulmonary diseases. Chief Executive Christy Shaffer said Inspire has reported the results to Allergan and "will be conducting a thorough review of the program before determining next steps, if any." At the end of the six-week study, Inspire gauged subjects extent of dry eye with a "staining score," in which patterns made by a stain are used to measure damaged cells in the central area of the cornea. It aimed to have a proportion of its subjects receiving Prolacria have a staining score of zero compared to a placebo group, its primary endpoint. It also failed to reduce the staining score by two units compared to the control group, the secondary endpoint. Dry eye occurs when the eye isn't being sufficiently lubricated. In November, the drug company reported a narrower third-quarter loss thanks to double-digit growth in sales. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291;

Stock News for Allergan (AGN)
07/25/201611:30:00Allergan Receives Positive Opinion For Truberzi® (Eluxadoline...
07/21/201612:50:00Amgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/21/201612:37:00Amgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/21/201609:00:00Amgen And Allergan Announce Top-Line Results From Phase 3 Study...
07/20/201618:20:00Jury Acquits Former Johnson & Johnson Unit Executives of Felony...
07/20/201618:06:00Jury Acquits Former Johnson & Johnson Unit Executives of Felony...
07/20/201607:59:00Actress Marisa Tomei Partners with Allergan to Raise Awareness...
07/19/201607:59:00Allergan and Adamas Announce New Expanded Indication for NAMZARIC®...
07/18/201618:11:00Teva Sells $15 Billion of Bonds
07/18/201617:46:00ADRs End Higher; ARM Holdings Soars
07/18/201615:03:00Teva Finalizes Bond Sale -- Update
07/18/201614:10:00Teva Finalizes Bond Sale
07/18/201613:51:00Teva Finalizes Bond Sale
07/18/201608:05:00Allergan Files Application to FDA for Approval of Oculeve Intranasal...
07/15/201607:30:00Market Updates on Drugs - Generic Equities -- Mylan, Horizon...
07/13/201609:50:00Teva, Allergan Tweak Acquisition Agreement
07/13/201609:31:00Teva, Allergan Tweak Acquisition Agreement
07/13/201606:52:00Current Report Filing (8-k)
07/12/201619:20:00Teva Raises Guidance
07/12/201619:04:00Teva Raises Guidance

Allergan and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations